Sawa 2013 KEN.

Methods	Trial design: RCT Follow‐up: Clinical assessment on days 1, 2, 3, 7, 14, 28, and 42 and any other time when child became ill. Blood smears taken on all follow‐up days except day 1. Adverse event monitoring: Not reported
Participants	Number of participants: 298 Inclusion criteria: Microscopically confirmed P. falciparum infection with asexual parasite density of 1,000 to 200,000 parasites/µL, tympanic temperature of ≥ 37.5 °C or history of fever in preceding 24 hrs, age 6 months to 10 years, informed consent Exclusion criteria: Hb level of < 5 g/dL, presence of any other Plasmodium species, presence of other febrile disease, severe malaria, history of adverse events with trial drugs
Interventions	1. DHA‐P, fixed dose combination, 40 mg/320 mg tablets (Duocotexin: Holley Pharm) Total dose: DHA 6.4 mg/kg + P 51.2 mg/kg in 3 equally divided doses, given once daily for 3 days Dose rounded off to nearest half tablet 2. Artemether‐lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem: Novartis) Half tablet per 5 kg body weight Dose rounded to nearest half tablet All doses were supervised. All participants advised to take each dose with fatty food to facilitate absorption.
Outcomes	Parasitological efficacy at days 42 and 28, PCR‐adjusted and PCR‐unadjusted Gametocyte carriage after treatment Not included in the review: Malaria transmission to mosquitoes
Notes	Country: Kenya Setting: Community setting Transmission: Moderate transmission intensity Resistance: None reported Dates: Apr to Jun 2009 Funding: Grants from the European Community’s Seventh Framework Programme and the Bill and Melinda Gates Foundation
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"A randomization list was generated for different age strata (<2 years, 2–5 years, and 5–10 years), using MS Excel".
Allocation concealment (selection bias)	Unclear risk	Allocation concealment is not reported.
Blinding for microscopy outcomes (performance bias and detection bias)	Low risk	"Except for those involved in administering medication, all staff members engaged in the trial were blinded to the treatment arm to which each child was assigned".
Blinding for adverse events (performance and detection bias)	Low risk	All staff blinded were except those administering drugs.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low number of patients without outcomes in both groups (DHA‐P 7.6%, AL6 5.2%).
Selective reporting (reporting bias)	Low risk	All WHO outcomes are reported.
Other bias	Low risk	No other sources of bias identified.